Beta Bionics Files 8-K on Financials
Ticker: BBNX · Form: 8-K · Filed: Oct 28, 2025 · CIK: 1674632
| Field | Detail |
|---|---|
| Company | Beta Bionics, Inc. (BBNX) |
| Form Type | 8-K |
| Filed Date | Oct 28, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Beta Bionics dropped an 8-K on Oct 28th covering financials. Check it out.
AI Summary
Beta Bionics, Inc. filed an 8-K on October 28, 2025, reporting on its Results of Operations and Financial Condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 11 Hughes, Irvine, California.
Why It Matters
This 8-K filing provides investors with crucial updates on Beta Bionics' financial performance and condition, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any unusual or high-risk events.
Key Players & Entities
- Beta Bionics, Inc. (company) — Registrant
- October 28, 2025 (date) — Date of earliest event reported
- 11 Hughes, Irvine, California 92618 (location) — Principal Executive Offices
- 001-42491 (company_id) — Commission File Number
FAQ
What specific financial information is being reported in this 8-K?
The 8-K filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filed?
The filing was made on October 28, 2025.
What is the principal business address of Beta Bionics, Inc.?
The principal executive offices are located at 11 Hughes, Irvine, California 92618.
What is Beta Bionics, Inc.'s Commission File Number?
Beta Bionics, Inc.'s Commission File Number is 001-42491.
What is the SIC code for Beta Bionics, Inc.?
The Standard Industrial Classification (SIC) code for Beta Bionics, Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 525 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-10-28 16:04:27
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share BBNX Nasdaq Global
Filing Documents
- f8k_102825.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 141KB
- 0001171843-25-006720.txt ( ) — 364KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_102825_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On October 28, 2025, Beta Bionics, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered "filed" or incorporated by reference therein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated October 28, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Beta Bionics, Inc. Date: October 28, 2025 By: /s/ Sean Saint Sean Saint President and Chief Executive Officer